Dominant immune response to HLA‐B57/B58 molecules after platelet transfusion

• DOI: 10.1111/trf.16116
• Publication Date: 2020-10-10T08:44:07Z
• Authors: Justine Coombs; Latifa Ben Hassen; Mathieu Leclerc; Marie Tamagne; Louise Pannetier; Mehdi Khelfa; Adèle Delorme; Thibaut Bocquet; Sébastien Maury; France Pirenne; Hélène Ansart‐Pir...; Benoît Vingert
• Keywords: Platelet Transfusion

Abstract Background Patients with hematologic malignancies require prophylactic or curative platelet transfusions to prevent treat bleeding. Treatments such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation cause persistent thrombocytopenia, necessitating transfusions. However, class I HLA antibodies can a serious complication: immune‐mediated refractoriness. The mechanisms of alloimmunization are incompletely understood. We explored the immunogenicity molecules phenotype HLA‐specific CD4 + T cells involved in alloimmunization. Study Design Methods investigated role transfusion retrospective cohort study on men specific anti‐HLA who had undergone transfusion. presence phenotypic profile alloimmunized patients included long‐term programs for malignancies. Results More than 50% transfused subjects displayed an antibody response against HLA‐B57 ‐B58. HLA‐B57–specific T‐cell responses were observed HLA‐B57. Following stimulation, presented producing tumor necrosis factor‐α, interleukin (IL)‐13, IL‐17A, IL‐2, IL‐10, IL‐21. Conclusion These results shed light posttransfusion constitute first step toward developing new strategies reducing